TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. is a biopharmaceutical company specializing in the development and commercialization of drugs and diagnostics for metastatic disease treatment and identification. Their lead therapeutic candidate, TTX-MC138, targets metastatic cancer. The company's preclinical programs include siRNA-based modulators of programmed death-ligand 1 and RNA-binding protein LIN28B. Additionally, they have cancer agnostic programs such as RNA-based agonists of the RIG-I-driven immune response, CRISPR/Cas9-based therapy platform, and mRNA-based cancer vaccines. These products are designed to activate cytotoxic immune responses against tumor cells, positioning the company at the forefront of innovative cancer treatment solutions.

Products

• TTX-MC138 - Therapeutic candidate for metastatic cancer

• TTX-siPDL1 - siRNA-based modulator of programmed death-ligand 1

• TTX-siLIN28B - siRNA-based inhibitor of RNA-binding protein LIN28B

• TTX-RIGA - RNA-based agonist of the RIG-I-driven immune response in the tumor microenvironment

• TTX-CRISPR - CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells

• TTX-mRNA - mRNA-based platform for the development of cancer vaccines